Drug interactions with itraconazole, fluconazole, and terbinafine and their management

Journal of the American Academy of Dermatology

Volumn 41, Issue 2 I, 1999, Pages 237-249

  Gupta, A K ^a   Katz, H I ^a   Shear, N H ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ASTEMIZOLE; BUSPIRONE; BUSULFAN; CARBAMAZEPINE; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; FELODIPINE; FLUCONAZOLE; FLUOXETINE; INDINAVIR; ISONIAZID; ITRACONAZOLE; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; PHENOBARBITAL; PHENYTOIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SIMVASTATIN; TERBINAFINE; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; DRUG ANTAGONISM; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVATION; HUMAN; PRIORITY JOURNAL;

EID: 0032811510     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(99)70055-1     Document Type: Article

References (225)

1. AK Gupta DN Sauder NH. Shear Antifungal agents: an overview. Part II J Am Acad Dermatol 30 1994 911 933
2. Gupta AK, Shear NH. An update, with a risk-benefit evaluation of the newer antifungal agents to treat onychomycosis. Drug Safety In press.
3. AS Nies SP. Spielberg Principles of therapeutics 9th ed JG Hardman LE Limbrid Goodman and Gilman’s The pharmacological basis of therapeutics. 1996 McGraw-Hill New York 43 62
4. Boston Collaborative Drug Surveillance Program Adverse drug interactions JAMA 220 1972 1238 1239
5. The assessment of risk in the clinical outcome of drug interactions PD Hansten JR Horn Drug interactions analysis and management. 1997 Applied Therapeutics Vancouver (WA) 481 493
6. JL Lipton LA Bero SJ. McPhee The impact of clinical pharmacist consultations on physicians’ geriatric drug prescribing Med Care 30 1992 646 658
7. Patients at increased risk for adverse drug reactions PD Hansten JR Horn Drug interactions analysis and management. 1997 Applied Therapeutics Inc Vancouver (WA) 495 498
8. IR. Edwards Pharmacological basis of adverse drug reactions 4th edition TM Speight NH Holford Avery’s Drug treatment. 1997 Adis International Ltd Auckland (NZ) 261 299
9. EA Hartshorn DS. Tatro Principles of drug interactions DS Tatro Drug interaction facts. 1998 Facts and Comparisons St Louis (MO) xix xxvi
10. F Sjöqvist O Borgå M-L Dahl ML’E. Orme Fundamentals of clinical pharmacology TM Speight HG Holford Avery’s Drug treatment. 1997 Adis International Ltd Auckland (NZ) 1 73
11. RL Slaughter DJ. Edwards Recent advances: the cytochrome P450 enzymes Ann Pharmacother 29 1995 619 624
12. EL. Michalets Update: clinically significant cytochrome P-450 drug interactions Pharmacotherapy 18 1998 84 112
13. DW Nebert M Adesnich MJ Coon RW Estabrook FJ Gonzalez FP Guengerich The P450 gene superfamily: recommended nomenclature DNA 6 1987 1 11
14. DS. Riddick Drug biotransformation 6th ed H Kalant W Roschlau Principles of medical pharmacology. 1998 Oxford University Press New York 38 54
15. MI Singer LE Shapiro NH. Shear Cytochrome P-450 3A: interactions with dermatologic therapies J Am Acad Dermatol 37 1997 765 771
16. KL Kunze LC Wienkers KE Thummel WF. Trager Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies Drug Metab Dispos 24 1996 414 421
17. DJ Black KL Kunze LC Wienkers BE Gidal TL Seaton ND McDonnell Warfarin-fluconazole II. A metabolically based drug interaction: in vitro studies Drug Metab Disp 24 1995 422 428
18. CE Cook GE Sklar JM. Nappi Possible pharmacokinetic interaction with quinidine: Ciprofloxacin or metronidazole? Ann Pharmacother 30 1996 364 366
19. MJ Cupp TS. Tracy Role of the cytochrome P450 3A subfamily in drug interactions US Pharmacist 1997 HS9 HS21
20. KLR Brouwer GE Dukes JR. Powell Influence of liver function on drug disposition 3rd ed WE Evans JJ Schentag WJ Jusko Applied pharmacokinetics: principles of therapeutic drug monitoring. 1992 Applied Therapeutics Spokane (WA) 1 59
21. LD Heimark L Wienkers K Kunze M Gibaldi AC Eddy WF Trager The mechanism of the interaction between amiodarone and warfarin in humans Clin Pharmacol Ther 51 1992 398 407
22. RT. Coutts Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping J Psychiatry Neurosci 19 1994 30 44
23. J Soto MJ Alsar JA. Sacristan Assessment of the time course of drugs with inhibitory effects of hepatic metabolic activity using successive salivary caffeine tests Pharmacotherapy 15 1995 781 784
24. A Van Peer R Woestenborghs J Heykants R Gasparini G. Cauwenbergh The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects Eur J Clin Pharmacol 36 1989 423 426
25. T Zimmermann RA Yeates H Laufen G Pfaff A. Wildfeuer Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole Eur J Clin Pharmacol 46 1994 147 150
26. JA Barone JG Koh RH Bierman JL Colaizzi KA Swanson MC Gaffar Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers Antimicrob Agents Chemother 37 1993 778 784
27. JM. Wishart The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection J Am Acad Dermatol 17 1987 220 223
28. D Feola RP. Rapp Effect of food intake on the bioavailability of itraconazole Clin Inf Dis 25 1997 344 345
29. 2 blockers J Clin Pharmacol 37 1997 535 540
30. S Jaruratanasirikul A. Kleepkaew Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole Eur J Clin Pharmacol 52 1997 235 237
31. IH. Stockley Drug interactions 4th ed 1996 Pharmaceutic Press London
32. TW Chin M Leob IW. Fong Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole Antimicrob Agents Chemother 39 1995 1671 1675
33. F Moreno TC Hardin MG Rinaldi JR. Graybill Itraconazole-didanosine excipient interaction [letter] JAMA 269 1993 1508
34. DB May RH Drew KC Yedinak JA. Bartlett Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers Pharmacotherapy 14 1994 509 513
35. Itraconazole oral solution package insert February 1997 Janssen Pharmaceutica Inc Titusville (NJ)
36. VJ Van de Velde AP Van Per JJ Heykants RJ Woestenborghs P Van Rooy KL De Beule Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole Pharmacotherapy 16 1996 424 428
37. Fluconazole package insert February 1997 Pfizer Roerig New York
38. JE Thorpe N Baker M. Bromet-Petit Effect of oral antacid administration on the pharmacokinetics of oral fluconazole Antimicrob Agents Chemother 34 1990 2032 2033
39. JW Van Der Meer JJ Keuning HW Scheijgrond J Heykants J Van Cutsem J. Brugmans The influence of gastric acidity on the bio-availability of ketoconazole J Antimicrob Chemother 6 1980 552 554
40. TK Daneshmend DW. Warnock Clinical pharmacokinetics of ketoconazole Clin Pharmacokinet 14 1988 13 34
41. RA Blum DT D’Andrea BM Florentino JH Wilton DM Hilligoss MJ Gardner Increased gastric pH and the bioavailability of fluconazole and ketoconazole Ann Intern Med 114 1991 755 757
42. SG Lim AM Sawyer M Hudson J Sercombe RE. Pounder Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity Ailment Pharmacol Ther 7 1993 317 321
43. DS Tatro Drug interaction facts. 1999 Facts and Comparisons St Louis (MO) 536
44. T Zimmerman RA Yeates K-D Riedel P Lach H. Laufen The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole Int J Clin Pharm Ther 32 1994 491 496
45. Itraconazole capsule package insert 1997 Janssen Pharmaceutica Inc Titusville (NJ)
46. MP Ducharme RL Slaughter LH Warbasse PH Chandrasekar V Van de Velde G Mannens Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin Clin Pharmacol Ther 58 1995 617 624
47. M Bonay AP Jonville-Bera P Diot E Lemarie M Lavandier E. Autret Possible interaction between phenobarbital, carbamazepine and itraconazole Drug Safety 9 1993 309 311
48. RM Tucker DW Denning LH Hanson MG Rinaldi JR Graybill PK Sharkey Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations Clin Infect Dis 14 1992 165 174
49. RA Lefebvre A Van Peer R. Woestenborghs Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole Br J Clin Pharmacol 43 1997 319 322
50. K Lavrijsen J Van Houdt W Meuldermans M Janssens J. Heykants The interaction of ketoconazole, itraconazole, and erythromycin with the in vitro metabolism of antihistamines in human liver microsomes Allergy 48 suppl 1993 34
51. JK Crane HT. Shih Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine Am J Med 95 1993 445 446
52. PK Honig DC Wortham R Hull K Zamani JE Smith LR. Cantilena Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics J Clin Pharmacol 33 1993 1201 1206
53. S Pohjola-Sintonen M Viitasalo L Toivonen P. Neuvonen Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia Eur J Clin Pharmacol 45 1993 191 193
54. LL von Moltke DJ Greenblatt SX Duan JS Harmatz CE Wright RI. Shader Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo J Clin Psychopharmacol 16 1996 104 112
55. S Pohjola-Sintonen M Viitasalo L Toivonene P. Neuvonen Tosades de pointes after terfenadine-itraconazole interaction BMJ 306 1993 186
56. M Blomley EL Teare A de Belder Y Thway M. Weston Itraconazole and anti-tuberculosis drugs [letter] Lancet 336 1990 1255
57. J Drayton G Dickinson MG. Rinaldi Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole [letter] Clin Infect Dis 18 1994 266
58. A Lefort O Launay C. Carbon Uveitis associated with rifabutin prophylaxis and itraconazole therapy [letter] Ann Intern Med 125 1996 939 940
59. A Varhe KT Olkkola PJ. Neuvonen Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 56 1994 601 607
60. KT Olkkola JT Backman PJ. Neuvonen Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole Clin Pharmacol Ther 55 1994 481 485
61. PJ Neuvonen A Varhe KT. Olkkola The effect of ingestion time interval on the interaction between itraconazole and triazolam Clin Pharmacol Ther 60 1996 326 331
62. J Ahonen KT Olkkola PJ. Neuvonen Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers Br J Clin Pharmacol 40 1995 270 272
63. LL von Moltke DJ Greenblatt J Schmider SX Duan CE Wright JS Harmatz Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents J Clin Pharmacol 36 1996 783 791
64. KT Olkkola J Ahonen PJ. Neuvonen The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam Anesth Analg 82 1996 511 516
65. J Ahonen KT Olkkola PJ. Neuvonen Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam Ther Drug Monit 18 1996 124 127
66. J Ahonen KT Olkkola PJ. Neuvonen The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam Fundam Clin Pharmacol 10 1996 314 318
67. Alprazolam package insert prescribing information 1996 Pharmacia and Upjohn Company Kalamazoo (MI)
68. KT Kivistö TS Lamberg T Kantola PJ. Neuvonen Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole Clin Pharmacol Ther 62 1997 348 354
69. I Buggia M Zecca EP Alessandrino F Locatelli G Rosti A Bosi Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation Anticancer Research 16 1996 2083 2088
70. PJ Neuvonen R. Suhonen Itraconazole interacts with felodipine J Am Acad Dermatol 33 1995 134 135
71. KM Jalava KT Olkkola PJ. Neuvonen Itraconazole greatly increases plasma concentrations and effects of felodipine Clin Pharmacol Ther 61 1997 410 415
72. SA Tailor AK Gupta SE Walter NH. Shear Peripheral edema due to nifedipine-itraconazole reaction: a case report [letter] Arch Dermatol 132 1996 350 352
73. DS Threlkeld Drug facts and comparisons. 1998 Facts and Comparisons St Louis (MO)
74. JT Kwan PJ Foxall DG Davidson MR Bending AJ. Eisinger Interaction of cyclosporine and itraconazole [letter] Lancet 2 1987 282
75. D Trenk W Brett E Jähnchen D. Birnbaum Time course of cyclosporin/itraconazole interaction [letter] Lancet 2 1987 13356
76. I Nováková P Donnelly T de Witte B de Pauw J Boezeman G. Veltman Itraconazole and cyclosporin nephrotoxicity [letter] Lancet 2 1987 920 921
77. MR Kramer SE Marshall DW Denning AM Keogh RM Tucker JN Galgiani Cyclosporine and itraconazole interaction in heart and lung transplant recipients Ann Intern Med 113 1990 327 329
78. DJ Back JF. Tjia Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole, and terbinafine on the metabolism of cyclosporin by human liver microsomes Br J Clin Pharmacol 32 1991 624 626
79. MA Shaw M Gumbleton PJ. Nicholls Interaction of cyclosporin and itraconazole Lancet 2 1987 637
80. J Berenguer NM Ali MC Allende J Lee K Garrett S Battaglia Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma Antimicrob Agents Chemother 38 1994 1303 1308
81. J. Rex Itraconazole-digoxin interaction [letter] Ann Intern Med 116 1992 525
82. MK Sachs LM Blanchard PJ. Green Interaction of itraconazole and digoxin Clin Infect Dis 16 1993 400 403
83. KL McClean GJ. Sheehan Interaction between itraconazole and digoxin [letter] Clin Infect Dis 18 1994 259 260
84. RHB Meyboom K de Jonge H Veentjer JAM Dekens-Konter GHP. de Koning Potentiation of digoxin by itraconazole Ned Tijdschr Geneeskd 138 1994 2353 2356
85. CA Kauffman FA. Bagnasco Digoxin toxicity associated with itraconazole therapy [letter] Clin Infect Dis 15 1992 886 887
86. CP Alderman HPA. Jersmann Digoxin-itraconazole interaction Med J Aus 159 1993 838 839
87. CP Aldermann PD. Allcroft Digoxin-itraconazole interaction: possible mechanisms Ann Pharmacother 31 1997 438 440
88. LA Cone RB Himelman JN Hirschberg JW. Hutcheson Itraconazole-related amaurosis and vomiting due to digoxin toxicity West J Med 165 1996 322
89. J Partanen K-M Jalava PJ. Neuvonen Itraconazole increases serum digoxin concentration Pharmacol Toxicol 79 1996 274 276
90. KM Jalava J Partanen PH. Neuvonen Itraconazole decreases renal clearance of digoxin Therap Drug Monit 19 1997 609 613
91. S Ito G. Koren Possible mechanism of digoxin-itraconazole interaction Ann Pharmacother 31 1997 1091 1092
92. PN. Black Probable interaction between fluoxetine and itraconazole Ann Pharmacother 29 1995 1048 1049
93. Henrivaux PH, Fairon Y, Fillet G. Pharmacokinetics of AZT among HIV infected patients treated by itraconazole [abstract] . Presented at the 5th International Conference on AIDS, June 4-9, 1989. Montreal, Quebec, Canada.
94. LL von Moltke DJ Greenblatt JM Grassi BW Granda SX Duan SM Fogelman Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir J Clin Pharmacol 38 1998 106 111
95. PJ Neuvonen K-M. Jalava Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid Clin Pharmacol Ther 60 1996 54 61
96. RS Lees AM. Lees Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole [letter] N Engl J Med 333 1995 664 665
97. M. Horn Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals [letter] Arch Dermatol 132 1996 1254
98. T Kantola KT Kivisto PJ. Neuvonen Differential effects of itraconazole on fluvastatin and lovastatin pharmacokinetics [abstract] Eur J Clin Pharmacol 52 suppl 1997 A134
99. MF Seagaert C de Soete I Vandewiele J. Verbanck Drug-interaction-induced rhabdomyolysis Nephrol Dial Transplant 11 1996 1846 1847
100. JP Desager Y. Horsmans Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Clin Pharmacokinet 31 1996 348 371
101. M Boberg R Angerbauer P Fey WK Kanhai W Karl A Kern Metabolism of cerivastatin by human liver microsomes in vitro: characterization of primary metabolic pathways and of cytochrome P450 isozymes involved Drug Metab Dispos 25 1997 321 331
102. PJ Neuvonen T Kantola KT. Kivistó Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clin Pharmacol Ther 63 1998 332 341
103. P Phillips JR Graybill R Fetchick JF. Dunn Adrenal response to corticotropin during therapy with itraconazole Antimicrob Agents Chemother 31 1987 647 649
104. H Linthoudt D van Raemdonck T Lerut M Demedts G. Verleden The association of itraconazole and methylprednisolone may give rise to important steroid-related side effects J Heart Lung Transplant 15 1996 1165
105. PI Pillans MJ. Sparrow Pregnancy associated with a combined oral contraceptive and itraconazole [letter] N Z Med J 106 1993 436
106. RH Meyboom EP van Puijenbroek MH Vinks CJ. Lastdrager Disturbance of withdrawal bleeding during concomitant use of itraconazole and oral contraceptives N Z Med J 110 1997 300
107. V Van de Velde R DeCoster R Doolaege R Woestenborghs K Groen J Del Rosso No indication of decrease in plasma levels of oral contraceptives after 15 days itraconazole administration in premenopausal women Aust J Dermatol 38 suppl 1997 283
108. Z Damanhouri M Gumbleton PJ Nicholls M. Shaw In-vivo effects of itraconazole on hepatic mixed-function oxidase J Antimicrob Chemother 21 1988 187 194
109. ME Veronese PI Mackenzie CJ Doecke ME McManus JO Miners DJ. Birkett Tolbutamide and phenytoin hydroxylation by cDNA-expressed human liver cytochrome P4502C9 Biochem Biophys Res Comm 175 1991 1112 1118
110. ME Veronese ME McManus P Laupattarakasem JO Miners DJ. Birkett Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450 Drug Metab Dispos 18 1990 356 361
111. A Rieutord I Stupans M Shenfield AS. Gross Gliclazide hydroxylation by rat liver microsomes Xenobiotica 25 1995 1345 1354
112. Glimepiride (Amaryl) prescribing information November 1996 Hoechst-Roussel Pharmaceuticals Kansas City (MO)
113. M Gumbleton Tolbutamide pharmacokinetics, in the presence of itraconazole, in the rat [abstract] J Pharm Pharmacol 39 suppl 1987 150P
114. Metformin (Glucophage) product information June 1996 Bristol-Myers Squibb Company Princeton (NJ)
115. Acarbose (Precose) product information March 1998 Bayer Corp West Haven (CT)
116. Troglitazone (Rezulin) product information January 1997 Parke-Davis Parsippany (NJ)
117. Repaglinide (Prandin) product information December 1997 NovoNordisk Pharmaceuticals Princeton (NJ)
118. J Verspeelt P De Doncker K Groen G Marynissen P Stoffels A. Heremans Tolerability and safety of itraconazole in diabetics [abstract] Australas J Dermatol 39 suppl 1997 290
119. E Lukkari A Juhakoski K Aranko PJ. Neuvonen Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite Eur J Clin Pharmacol 52 1997 403 406
120. RM McNulty JA Lazor M. Sketch Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy Clin Pharm 8 1989 222 225
121. KM Kaukonen KT Olkkola PJ. Neuvonen Itraconazole increases plasma concentrations of quinidine Clin Pharmacol Ther 62 1997 510 517
122. Sildenafil citrate (ViagraTM) package insert March 1998 Pfizer Laboratories New York
123. MR Kramer G Merin E Rudis I Bar T Nesher M Bublil Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506) Transplant Proc 29 1997 2657 2659
124. TN Prasad DD Stiff N Subbotina MA Zemaitis GJ Burckart TE Starzl FK 506 (tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs Res Commun Chem Pathol Pharmacol 84 1994 35
125. V Furlan F Parquin JF Penaud J Cerrina FL Ladurie P Dartevelle Interactions between tacrolimus and itraconazole in heart-lung transplant recipient Transplant Proc 32 1998 187 188
126. A Böhme A Ganser D. Hoelzer Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL Ann Hematol 71 1995 311 312
127. JA Murphy LM Ross BES. Gibson Vincristine toxicity in five children with acute lymphoblastic leukaemia [letter] Lancet 346 1995 443
128. J Yeh SG Soo C Summerton C. Richardson Potentiation of action of warfarin by itraconazole [letter] Br Med J 301 1990 669
129. DL Newberry SN Bass CO. Mbanefo A fluconazole/amitriptyline drug interaction in three male adults Clin Infect Dis 24 1997 270 271
130. RH Gannon ML. Anderson Fluconazole-nortriptyline drug interaction Ann Pharmacother 26 1992 1456 1457
131. PK Honig DC Wortham K Zamani JC Mullin DP Conner LR. Cantilena The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans Clin Pharmacol Ther 53 1993 630 636
132. KT Kivisto PJ Neuvonen U. Klotz Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences Clin Pharmacokinet 27 1994 1 5
133. LR Cantilena S Sorrels T Wiley D. Wortham Fluconazole alters terfenadine pharmacokinetics and electrocardiographic pharmacodynamics [abstract] Clin Pharmacol Ther 57 1995 185
134. M Jurima-Romet K Crawford T Cyr T. Inaba In vitro inhibition by macrolide antibiotics and azole antifungals Drug Metab Dispos 22 1994 849 857
135. VL Bruzzese JG Gillum DS Israel GL Johnson LG Kaplowitz RE. Polk Effect of fluconazole on pharmacokinetics of 2′,3′-dideoxyinosine in persons seropositive for human immunodeficiency virus Antimicrob Agents Chemother 39 1995 1050 1053
136. J Sahai K Gallicano A Pakuts DW. Cameron Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus J Infect Dis 169 1994 1103 1107
137. E Sampol B Lacarelle JF Rajaonarison J Catalin A. Durand Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes Br J Clin Pharmacol 40 1995 83 86
138. S De Wit M Debier M De Smet J McCrea J Stone A Carides Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 42 1998 223 227
139. A Cato III G Cao A Hsu J Cavanaugh J Leonard R. Granneman Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir Drug Metab Dispos 25 1997 1104 1106
140. MT Borin SR Cox BD Herman BJ Carel RD Anderson WW. Freimuth Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients Antimicrob Agents Chemother 41 1997 1892 1897
141. M Brockmeyer I Tillmann L Mertins L Mertins B Barthel M. Goos Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients Eur J Med Res 2 1997 377 383
142. G Apseloff DM Hilligoss MJ Gardner EB Henry PB Inskeep N Gerber Induction of fluconazole metabolism by rifampin: in vivo study in humans J Clin Pharmacol 31 1991 358 361
143. RJ Coker DR Tomlinson J Parkin JRW Harris AJ. Pinching Interaction between fluconazole and rifampicin [letter] Br Med J 301 1990 818
144. DP Nicolau HM Crowe CH Nightingale R. Quintiliani Rifampin-fluconazole interaction in critically ill patients Ann Pharmacother 29 1995 994 996
145. S Jaruratanasirikul A. Kleepkaew Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients J Antimicrob Chemother 38 1996 877 880
146. CB Trapnell PK Narang R Li JP. Lavelle Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients Ann Intern Med 124 1996 573 576
147. PK Narang CB Trapnell JR Schoenfelder JP Lavelle JR. Bianchine Fluconazole and enhanced effect of rifabutin prophylaxis [letter] N Engl J Med 330 1994 1316 1317
148. CB Trapnell C Jamis-Dow RW Klecker JM. Collins Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole Antimicrob Ag Chemoth 41 1997 924 926
149. MJ Mattila P Vainio J. Vanakoski Fluconazole moderately increases midazolam effects on performance [abstract] Br J Clin Pharmacol 39 1995 567P
150. J Vanakoski MJ Mattila P Vainio JJ Idänpään-Heikkilä M. Törnwall 150 mg Fluconazole does not substantially increase the effects of 10 mg midazolam or the plasma midazolam concentration in healthy subjects Int J Clin Pharmacol Ther 33 1995 518 523
151. J Ahonen KT Olkkola PJ. Neuvonen Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam Eur J Clin Pharmacol 51 1997 415 419
152. A Varhe KT Olkkola PJ. Neuvonen Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism Br J Clin Pharmacol 41 1996 319 323
153. A Varhe KT Olkkola PJ. Neuvonen Effect of fluconazole dose on the extent of fluconazole-triazolam interaction Br J Clin Pharmacol 42 1996 465 470
154. AM Baciewicz FA. Baciewicz Ketoconazole and fluconazole drug interactions Arch Int Med 153 1993 1970 1976
155. JA. Lopez-Gil Fluconazole-cyclosporine interaction: A dose-dependent effect? Ann Pharmacother 27 1993 427 430
156. P Collignon B Hurley D. Mitchell Interaction of fluconazole with cyclosporin [letter] Lancet 1 1989 1262
157. HU Kruger U Schuler R Zimmer G. Ehninger No severe interactions between fluconazole, a triazole antifungal agent, with cyclosporin Bone Marrow Transplant 3 1988 271
158. G Ehninger K Jaschonek U Schuler HU. Krüger Interaction of fluconazole with cyclosporin [letter] Lancet 2 1989 104 105
159. DM Canafax NM Graves DM Hilligoss BC Carelton MJ Gardner AJ. Matas Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study Transplant Proc 23 1991 1041
160. HU Kruger U Schuler R Zimmermann G. Ehninger Absence of significant interaction of fluconazole with cyclosporin J Antimicrob Chemother 24 1989 781 786
161. V Torregrosa M de la Torre JM Campistol F Oppenheimer MJ Ricart J Vilardell Interaction of fluconazole with cyclosporin A [letter] Nephron 60 1992 125 126
162. P Collignon B. Hurley Interaction between fluconazole and cyclosporin [letter] Lancet 2 1989 867 868
163. AM Sugar C Saunders BA Idelson DB. Bernard Interaction of fluconazole and cyclosporine Ann Intern Med 110 1989 844
164. DM Canafax NM Graves DM Hilligoss BC Carleton MJ Gardner AJ. Matas Interaction between cyclosporine and fluconazole in renal allograft recipients Transplantation 51 1991 1014 1018
165. MH Devenport D Crook V Wynn LJ. Lees Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives Br J Clin Pharmacol 27 1989 851
166. FE Sinofsky SA. Pasquale The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives Am J Obstet Gynecol 178 1998 300 304
167. BR Rowe J Thorpe A. Barnett Safety of fluconazole in women taking oral hypoglycaemic agents [letter] Lancet 339 1992 255 256
168. Fluconazole package insert February 1997 Pfizer Roerig New York
169. KM Howitt MA. Oziemski Phenytoin toxicity induced by fluconazole [letter] Med J Aust 151 1989 603 604
170. AS Mitchell JT. Holland Fluconazole and phenytoin: a predictable interaction Br Med J 298 1989 1315
171. RM Cadle GJ Zenon 3rd MC Rodriguez-Barradas RJ. Hamill Fluconazole-induced symptomatic phenytoin toxicity Ann Pharmacother 28 1994 191 195
172. JD Lazar KD. Wilner Drug interactions with fluconazole Rev Infect Dis 12 suppl 1990 S327 S333
173. RA Blum JH Wilton DM Hilligoss MJ Gardner EB Henry NJ Harrison Effect of fluconazole on the disposition of phenytoin Clin Pharmacol Ther 49 1991 420 425
174. MA Touchette PH Chandrasekar MA Milad DJ. Edwards Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man Br J Clin Pharmacol 34 1992 75 78
175. S Tett D Carey H-S. Lee Drug interactions with fluconazole [letter] Med J Aust 156 1992 365
176. RH. Levy Cytochrome P450 isozymes and antiepileptic drug interactions Epilepsia 36 suppl 1995 S8 S13
177. R Mañez M Martin V Raman D Silverman A Jain V Warty Fluconazole therapy in transplant recipients receiving FK506 Transplantation 57 1994 1521 1523
178. CL Osowski SP Dix LS Lin RE Mullins RB Geller JR. Wingard Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients Transplantation 61 1996 1268 1272
179. A Dhawan JM Tredger PJ North-Lewis CE Gonde AP Mowat NJ. Heaton Tacrolimus (FK506) malabsorption: management with fluconazole coadministration Transpl Int 10 1997 331 334
180. R Assan G Fredj E Larger G Feutren H. Bismuth FK 506/fluconazole interaction enhances FK 506 nephrotoxicity Diabetes Metab 20 1994 49 52
181. K Iwasaki H Matsuda K Nagase T Shiraga Y Tokuma K. Uchida Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes Res Comm Chem Pathol Pharmacol 82 1993 209 216
182. H Konishi K Morita A. Yamaji Effect of fluconazole on theophylline disposition in humans Eur J Clin Pharmacol 46 1994 309 312
183. TL Seaton CL Celum DJ. Black Possible potentiation of warfarin by fluconazole Ann Pharmacother 24 1990 1177 1178
184. DJ Black BE Gidal KL Kunze BS Evans JE Bauwens SH Petersdorf An evaluation of the effect of fluconazole (F) on the stereoselective metabolism of warfarin (W) [abstract] Clin Pharmacol Ther 51 1992 184
185. KR. Gericke Possible interaction between warfarin and fluconazole Pharmacotherapy 13 1993 508 509
186. AM Baciewicz JJ Menke JA Bokar EB. Baud Fluconazole-warfarin interaction [letter] Ann Pharmacother 28 1994 1111
187. HD. Kerr Case report: potentiation of warfarin by fluconazole Am J Med Sci 305 1993 164 165
188. LL Crussel-Porter JP Rindone MA Ford DW. Jaskar Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium Arch Intern Med 153 1993 102 104
189. KL Kunze WF. Trager Warfarin-fluconazole III: a rational approach to management of a metabolically based drug interaction Drug Metab Disp 24 1995 429 435
190. A. Breckenridge Clinical significance of interactions with antifungal agents Br J Dermatol 126 suppl 1992 19 22
191. DJ Back JF Tjia SM. Abel Azoles, allylamines and drug metabolism Br J Dermatol 126 suppl 1992 14 18
192. I. Schuster Potential of allylamines to inhibit cytochrome P-450 RA Fromtling Recent trends in the discovery, development and evaluation of antifungal agents. 1987 JR Prous Science Publisher Barcelona 471 478
193. I Schuster NS. Ryder Allylamines: mode and selectivity of action compared to azole antifungals and biological fate in mammalian organisms J Dermatol Treat 1 suppl 1990 7 9
194. I. Schuster The interaction of representative members from two classes of antimycotics: the azoles and the allylamines–with cytochrome P-450 in steroidogenic tissues and liver Xenobiotica 15 1985 529 546
195. DJ Back JF. Tija Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymes J Dermatol Treat 1 suppl 1990 11 13
196. DP O’Sullivan CA Needham A Bangs K Atkin FD. Kendall Postmarketing surveillance of oral terbinafine in UK: report of a large cohort study Br J Clin Pharmacol Ther 42 1996 559 565
197. M Hall C Monka P Krupp D. O’Sullivan Safety of oral terbinafine: results of a postmarking surveillance study in 25,884 patients Arch Dermatol 133 1997 1213 1219
198. JC Jensen DJ. Back Interaction of terbinafine with cytochrome P-450 in vitro and in vivo in man Br J Clin Pharmacol 26 1988 236P
199. IA Shah PH Whiting G Omar AD Ormerod MD. Burke The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin Br J Dermatol 129 1993 395 398
200. Terbinafine package insert May 1997 Novartis Pharmaceuticals East Hanover (NJ)
201. DJ Back P Stevenson JF. Tjia Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinylestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro Br J Clin Pharmacol 28 1989 166 170
202. HI Katz AK. Gupta Oral antifungal drug interactions Dermatol Clin 15 1997 535 544
203. B Robbins CT Chang JA Cramer S Garreffa B Hafkin TL Hunt Safe co-administration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers Clin Pharmacol Ther 59 1996 275 283
204. J Ahonen KT Olkkola PJ. Neuvonen Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamic of midazolam in healthy volunteers Br J Clin Pharmacol 40 1995 270 272
205. JA Cramer BA Robbins TC Bedman AI Dreisbach JA. Meligem Pharmacokinetic effects of single-dose terbinafine and single-dose sustained-release nifedipine co-administration in healthy volunteers [abstract] Pharmacol Res 13 1996 S436
206. A Tarral P Fracheteau M. Guerret Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers Pharmaco-therapy 17 1997 791 795
207. D Nashan UA Knuth G Weidinger E. Nieschlag The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary-testicular function of healthy men: a placebo-controlled double-blind trial Acta Endocrinol 120 1989 677 681
208. I Effendy W. Krause In vivo effects of terbinafine and ketoconazole on testosterone plasma levels in healthy males Dermatologica 178 1989 103 106
209. JA Cramer B Robbins R Barbesto S Kaatz JA. Meligeni Lamisil® interaction study in type II diabetes mellitus patients on stable glyburide therapy Pharmacol Res 13 1996 S436
210. R Seyffer M Eichelbaum JC Jensen U. Klotz Antipyrine metabolism is not affected by terbinafine, a new antifungal agent Eur J Clin Pharmacol 37 1989 231 233
211. R Suhonen PJ. Neuvonen The tolerability profile of terbinafine Rev Contemp Pharmacother 8 1997 373 386
212. CC Long SA Hill RC Thomas A Johnston SG Smith F Kendall Effect of terbinafine on the pharmacokinetics of cyclosporin in humans J Invest Dermatol 102 1994 740 743
213. A Walländer G. Paumgartner Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers Eur J Clin Pharmacol 37 1989 279 283
214. A Kalow BK. Tang The use of caffeine for enzyme assays: a critical appraisal Clin Pharmacol Ther 53 1993 503 514
215. EF Trépanier AN Nafziger GL Kearns ADM Kashuba GW. Amsder Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidate J Clin Pharmacol 38 1998 424 428
216. W Tasseneeyakul DJ Birkett ME McManus W Tassaneeyakul ME Veronese T Andersson Caffeine metabolism by human hepatic cytochrome P450: contributions of 1A2, 2E1 and 3A isoforms Biochem Pharmacol 47 1994 1767 1776
217. P Jensen G Leone P Faucal S. Simons Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection Acta Derm Venereol (Stockh) 76 1996 280 281
218. AC Lo SL Lui WK Lo DT. Chan IK. Cheng The interaction of terbinafine and cyclosporine A in renal transplant patients Br J Clin Pharmacol 43 1997 340 341
219. P-H.M Van der Kuy PM. Hooymans Nortriptyline intoxication induced by terbinafine Br Med J 318 1998 441
220. EF Trépanier AN Nafziger GW. Amsden Effect of terbinafine on theophylline pharmacokinetic in healthy volunteers Antimicrob Ag Chemother 42 1998 695 697
221. MA Sarkar BJ. Jackson Theophylline N-demethylations as probes for P4501A1 and P4501A2 Drug Metab Disp 22 1994 827 834
222. M Hubert S Kirkesseli P Francheteau K. Kutz Pharmacokinetic and pharmacodynamics interaction study with Lamisil® and warfarin in healthy volunteers: data on file: study codes SFW 410-E-00/001 1992 Novartis Pharma Basel
223. M Guerret P Francheteau M. Hubert Evaluation of effects of terbinafine on single oral dose pharmacokinetics and antiagulant actions of warfarin in healthy volunteers Pharmacotherapy 17 1997 767 773
224. JA Warwick RJ. Corrall Serious interaction between warfarin and oral terbinafine BMJ 318 1998 440
225. AK Gupta GS. Ross Interaction between terbinafine and warfarin Dermatology 196 1998 266 267